Abstract:Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor (TKI) and currently approved for use in advanced renal cell carcinoma (RCC). It is really attractive drug for patients who cannot have surgical treatment. However, it is reported that TKI might be substrates of ATP-binding cassette (ABC) transporters, which are able to mediate the efflux of anti-tumor drugs from the tumor cells. In this study, we suggested that inhibition of MDR transporters by elacridar (dual inhibitor of MDR-1 and ABCG2) might … Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.